Slate launched with $130M to go after PACAP, a migraine pathway that sits entirely outside the CGRP drugs already on the market.
CGRP inhibitors changed migraine treatment for a large share of patients over the last several years, but not everyone responds to them. A meaningful population has cycled through the current generation of preventives without adequate relief, and until now there has been no mechanistically distinct alternative in active development at comparable scale.
A launch built around a single, narrow mechanism
Slate launched with a $130 million Series A to develop an antibody targeting PACAP, a neuropeptide involved in migraine that sits outside the CGRP pathway targeted by every major migraine preventive currently approved. Phase 1 trials are expected to begin in the middle of 2026, which means the program is still early, but the size of the launch round signals real investor conviction in the underlying science.
Most well funded neurology launches over the last several years have clustered around mechanisms already validated by an approved drug, essentially betting on a better version of something known to work. Slate's approach is the opposite bet, that the CGRP non responder population is large enough, and underserved enough, to justify building an entirely new pathway rather than refining an existing one.
A genuinely different bet than most recent neurology launches
Launching with $130M against a single, narrowly defined mechanism is a bet that being genuinely different from the CGRP class matters more, right now, than being another entrant competing inside it, a contrarian position relative to how most neurology capital has been deployed recently.
That structural choice carries real risk alongside the potential reward. A validated mechanism, even a crowded one, comes with a clearer regulatory and commercial path. A genuinely novel target like PACAP is a bet on biology that has not yet been proven out in human trials at this scale, which is precisely why the round size is notable, investors are pricing in real conviction, not just optionality.
The readout that will actually settle this
Phase 1 data, expected sometime after trials begin, will be the first real signal of whether PACAP behaves the way the underlying science suggests once tested in humans. Migraine investors have been burned before by mechanisms that looked strong preclinically and underperformed in the clinic, so this is a program worth tracking through its first readout rather than treating the launch size itself as validation of the science.
Watch specifically for how Slate frames its Phase 1 endpoints once trials begin, since that framing will tell you how confident the company itself is in translating preclinical results into a human response.
